The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

SU2C, SandboxAQ collaborate to accelerate treatment innovation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Stand Up To Cancer and SandboxAQ announced a collaboration that brings SandboxAQ’s Large Quantitative Models to SU2C-funded cancer research projects. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?
By Sara Willa Ernst
In Brief

Curebound announces eight grants totaling $2M to address emerging areas of cancer research

Curebound has announced eight grants for a total of $2 million in funding. The funding is made available through two new Curebound programs: Catalyst Grants, which support projects within early-stage life science companies that are seeking to take innovative discoveries to commercially approved products, and Equity Grants, which focus on overcoming disparities in cancer research and treatment in underserved populations.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account